Iteos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

iTeos Therapeutics

10/05/2023 13:00

* Iteos Therapeutics Inc  ITOS.OQ  reported a quarterly
adjusted
loss of 44 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 99 cents per share.
    * Revenue fell 91.7% to $12.60 million from a year ago;
analysts
expected $8.04 million. 
    * Iteos Therapeutics Inc's reported EPS for the quarter was
a loss
of 44 cents​.
    * The mean earnings estimate of analysts had fallen by
about 678.9% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Iteos Therapeutics Inc shares had risen by 4.2% this
quarter and
lost 27.4% so far this year.
    * The company reported a quarterly loss of $15.55 million.
    * Wall Street's median 12-month price target for Iteos
Therapeutics Inc is $41.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.99          -0.44          Beat
 Dec. 31 2022      0.33                          
 Sep. 30 2022      0.10           0.03           Missed
 Jun. 30 2022      1.20           0.15           Missed